Covid 19 Cases in India LIVE Updates: Active cases surge past 4000; 5 new deaths reported
Covid 19 Cases in India 2025 LIVE News Updates: The active Covid-19 cases in India, amid the recent surge in infection, stand at 4026, according to the Ministry of Health and Family Welfare as of Tuesday, 8 am. Meanwhile, a total of five new Covid-19 deaths have been reported in the country. Kerala currently accounts for the highest number of Covid cases in the country, standing at 1416. Meanwhile, Karnataka, Haryana, Tamil Nadu and Gujarat recorded a sharp uptick in active cases over the last few days.
Why are Covid-19 cases on the rise again? While multiple countries are now reporting a fresh spike in Covid infections, the fatality rate remains low. Most of the people who are Covid-19 positive are displaying mild symptoms. One of the main reasons why cases are spiking is that the protection from vaccination or past infection decreases with time, leaving individuals more vulnerable to reinfection. Like other viruses, SARS-CoV-2 continues to mutate. Some of these new variants may spread more easily or evade immunity to a greater extent, triggering fresh surges.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Covid cases in India: Coronavirus cases cross 4,500; Kerala tops chart
India has reported a total of 4,866 active Covid-19 cases as of June 5, 2025, according to the Ministry of Health and Family Welfare. Kerala leads the chart with 1,487 cases, followed by Delhi (562), and West Bengal (538). Tired of too many ads? go ad free now The complete state-wise count includes Rajasthan (103), Maharashtra (526), and Gujarat (508), Karnataka (436), Tamil Nadu (213), Uttar Pradesh (198), Haryana (63), Bihar (31), Madhya Pradesh (30), Odisha (18), Punjab (16), Andhra Pradesh (50), Telangana (3), Jharkhand (8), Assam (8), Goa (8), Chhattisgarh (19), Uttarakhand (6), Sikkim (9), Jammu & Kashmir (5), Chandigarh (2), Puducherry (17), Himachal Pradesh (1). Seven regions — Tripura, Arunachal Pradesh, Manipur, Mizoram, Meghalaya, Nagaland, and Andaman & Nicobar Islands — have reported zero active cases. . Covid fatalities, however, underline a clear trend — people with pre-existing health problems remain highly vulnerable. In Delhi, a five-month-old infant with multiple health issues and an 87-year-old man with several chronic conditions died. Karnataka reported the deaths of a cancer patient and another with severe abdominal complications. Maharashtra recorded three deaths, including elderly patients with heart disease, cancer, diabetes, and organ failure. Globally, China, Singapore, Taiwan, and United States have reported the highest number of cases.
India.com
an hour ago
- India.com
COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases
COVID-19 Cases Rising In India Highlights: India is once again witnessing an unsettling rise in COVID-19 cases, with the number of active infections climbing to 4866, according to the Ministry of Health and Family Welfare's latest update as of 8:00 AM IST, June 5, 2025. Leading the current spike is Kerala pushing its active caseload to 1487, nearly half of the country's total. Meanwhile, West Bengal added 106 new cases, increasing its active tally to 538, while the national capital Delhi recorded 105 new infections, taking its active cases to 562. As per May 2025 classifications by the World Health Organization (WHO), subvariants LF.7 and NB.1.8.1 are categorized as Variants Under Monitoring, meaning they are not yet deemed as Variants of Concern or Variants of Interest. However, these strains are suspected to be contributing to the rising infections not just in India but also across China and other parts of Asia. Despite the emergence of new subvariants, the JN.1 strain remains the most dominant, accounting for a staggering 53% of all positive cases across the country. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), a case of NB.1.8.1 was detected in Tamil Nadu in April, while four cases of LF.7 were identified in Gujarat earlier this month. With the virus subtly shifting form and symptoms evolving, health authorities are urging the public to maintain precautionary measures, including hygiene, mask use in crowded places, and timely testing. Although hospitalisation remains low, experts warn that complacency could reverse progress. Stay informed, and if you're experiencing mild symptoms like fatigue, a sore throat, or gastrointestinal discomfort, it's best to test early and isolate to prevent further spread.
Time of India
an hour ago
- Time of India
A common drug shows promise for patients with liver disease
A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study, involving 154 participants, demonstrated significant improvements in MASH and fibrosis among those receiving dapagliflozin compared to the placebo group, suggesting a potential new treatment avenue. Liver disease accounts for two million deaths annually. This is 4% of all deaths (1 out of every 25 deaths worldwide), as per the data from 2023. Liver disease is a growing global health concern. A new study suggests that a widely used diabetes medication may offer hope for patients suffering from progressive liver disease. A recent clinical trial conducted in China and published in The BMJ suggests that the type 2 diabetes drug dapagliflozin can help patients with severe liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, which have limited treatment options. What does the diabetes drug do (Pic courtesy: iStock) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, which is widely used to treat type 2 diabetes, has been shown to improve progressive liver disease. The Chinese researchers found that the drug improved metabolic dysfunction-associated steatohepatitis (MASH), a condition where excess fat accumulates in the liver, leading to inflammation and liver fibrosis (a buildup of scar tissue). MASH affects more than 5% of adults, and it is also common (30%) in people with diabetes or obesity. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo This can progress to cirrhosis in up to 25% of individuals. Though previous studies have suggested that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, no trial has been carried out in patients with MASH. The study To understand the effects of dapagliflozin in patients with MASH, the researchers conducted a study. The 48-week study had 154 participants, who were diagnosed with MASH following liver biopsies at six Chinese medical centers from November 2018 to March 2023. Participants had an average age of 35, and 85% were men. Nearly half (45%0 had type 2 diabetes, and most had evidence of liver fibrosis at various stages (33% stage 1, 45% stage 2, 19% stage 3). Following an initial screening biopsy, the participants were randomly assigned to receive 10 mg of dapagliflozin or a matching placebo once daily for 48 weeks. They attended health education sessions twice a year. The researchers also recorded body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids of the participants throughout the trial. MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less. By the end of the study, which is after 48 weeks, the researchers observed that 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group. 23% (18 of 78) participants in the dapagliflozin group showed resolution of MASH without worsening of fibrosis, compared with 8% (6 of 76) in the placebo group. Trump Health Scare: 'Cognitive Decline' Spotted? Political Adviser's BIG Warning Amid Dementia Claim They also saw improvement in fibrosis without worsening of MASH in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group. 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group discontinued the treatment because of adverse events. What are the experts saying Fatty liver 'Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis,' they said. They added that large-scale and long-term trials are needed to further confirm these effects. The trial was conducted in a Chinese population, which limits its broader generalisability. They also noted that with the emergence of more drugs, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. 'Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,' they concluded. One step to a healthier you—join Times Health+ Yoga and feel the change
